Paragon Vision Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Paragon Vision Sciences's estimated annual revenue is currently $28.1M per year.
- Paragon Vision Sciences's estimated revenue per employee is $270,000
Employee Data
- Paragon Vision Sciences has 104 Employees.
- Paragon Vision Sciences grew their employee count by -10% last year.
Paragon Vision Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.7M | 25 | -22% | N/A | N/A |
#2 | $8.9M | 41 | -7% | N/A | N/A |
#3 | $10.8M | 50 | 47% | N/A | N/A |
#4 | $9.9M | 39 | 0% | N/A | N/A |
#5 | $51.1M | 172 | 5% | N/A | N/A |
#6 | $6.5M | 30 | -6% | N/A | N/A |
#7 | $20.5M | 76 | 1% | N/A | N/A |
#8 | $12.9M | 53 | 6% | N/A | N/A |
#9 | $8.9M | 41 | 11% | N/A | N/A |
#10 | $4.7M | 25 | 14% | N/A | N/A |
What Is Paragon Vision Sciences?
Paragon Vision Sciences is a world leader in orthokeratology (ortho-k), specialty contact lenses and oxygen permeable contact lens materials. As a progressive manufacturer of a full range of oxygen permeable (GP) materials used in the manufacturing of contact lenses, Paragon Vision Sciences developed Paragon CRT® Contact Lenses for use in orthokeratology. Approved by the FDA in June of 2002 for overnight wear, Paragon CRT® Contact Lenses are the preferred choice by an elite, global group of eye care practitioners to manage myopia (nearsightedness).
keywords:N/AN/A
Total Funding
104
Number of Employees
$28.1M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Paragon Vision Sciences News
Essilor Group, Johnson & Johnson, Luxottica, Novartis, Valeant Pharmaceuticals, Bausch and Lomb, Menicon, Paragon Vision Sciences,...
Ltd., Paragon Vision Sciences, Bausch & Lomb, OPRI Inc., PPG Optical, Benz Research & Development, X-Cel Optical Company.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23.3M | 106 | 8% | N/A |
#2 | $23.3M | 106 | 8% | N/A |
#3 | $19.4M | 108 | 4% | N/A |
#4 | $25M | 110 | 4% | N/A |
#5 | $36.1M | 111 | 41% | N/A |